Alpha 2.0
Login Register
» Authors » Tomoyuki Takashima

Tomoyuki Takashima

Explore the profile of Tomoyuki Takashima including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 106
Citations 880
Followers 0
Related Specialties
Gastroenterology
General Medicine
Oncology
Top 10 Co-Authors
Hirayuki Enomoto
Nobuhiro Aizawa
Naoto Ikeda
Hiroko Iijima
Shuhei Nishiguchi
Yoshinori Iwata
Takashi Nishimura
Yoshiyuki Sakai
Kazunori Yoh
Hiroki Nishikawa
Published In
Hepatol Res
J Clin Med
Medicine (Baltimore)
BMJ Open Gastroenterol
In Vivo
Affiliations
Soon will be listed here.
Recent Articles
1.
Possible Use of Body Surface Area Value for Estimating Skeletal Muscle Mass in Chronic Liver Disease
Yoh K, Nishimura T, Ikeda N, Takashima T, Aizawa N, Yuri Y, et al.
Diagnostics (Basel) . 2025 Feb; 15(3). PMID: 39941193
Sarcopenia is an important clinical feature of patients with chronic liver disease (CLD). However, special devices are required to determine skeletal muscle mass. We evaluated the usefulness of body surface...
2.
Long-term Effect of the HCV Elimination With Direct-acting Antivirals on the Progression of Gastroesophageal Varices
Yuri Y, Nishimura T, Ikeda N, Takashima T, Aizawa N, Kimura T, et al.
In Vivo . 2024 Oct; 38(6):2968-2972. PMID: 39477391
Background/aim: Gastroesophageal varices (GEV) hemorrhage is a serious complication that can lead to unfavorable outcomes in cirrhotic patients. However, the clinical impact of HCV elimination [sustained viral response (SVR)] by...
3.
Feasibility of Double-Deployment Small-Diameter Covered Metallic Stent for Malignant Distal Biliary Obstruction (with Video)
Nakano R, Shiomi H, Okamoto M, Kawase Y, Yoshihara K, Yoshioka R, et al.
Diagnostics (Basel) . 2024 Oct; 14(19). PMID: 39410637
Background/objectives: Covered self-expandable metallic stents (CSEMS) are commonly used to treat malignant distal biliary obstructions. A 10-mm CSEMS carries the risk of obstructing the pancreatic and cystic duct orifices by...
4.
Hepatic arterial infusion of autologous CD34 cells for hepatitis C virus-related decompensated cirrhosis: A multicenter, open-label, exploratory randomized controlled trial
Nakamura T, Masuda A, Kako M, Enomoto H, Kaibori M, Fujita Y, et al.
Regen Ther . 2024 May; 27:455-463. PMID: 38737403
Introduction: In this multicenter clinical study, we aimed to investigate the efficacy and safety of the transhepatic arterial administration of granulocyte-colony stimulating factor (G-CSF)-mobilized autologous peripheral blood (PB)-CD34 cells compared...
5.
VFMAP predicted hepatocellular carcinoma development in patients with chronic hepatitis C who were treated with direct-acting antiviral and achieved sustained virologic response
Matono T, Tada T, Nishimura T, Takashima T, Aizawa N, Ikeda N, et al.
J Med Ultrason (2001) . 2023 Dec; 51(2):293-300. PMID: 38147196
Purpose: Risk factors for the development of hepatocellular carcinoma (HCC) remain unclear in patients with hepatitis C virus (HCV) who achieve sustained virological response (SVR) after direct-acting antiviral (DAA) therapy....
6.
A Low Geriatric Nutritional Risk Index Is Associated with Low Muscle Volume and a Poor Prognosis among Cirrhotic Patients
Enomoto H, Yuri Y, Nishimura T, Ikeda N, Takashima T, Aizawa N, et al.
Medicina (Kaunas) . 2023 Dec; 59(12). PMID: 38138202
: The geriatric nutritional risk index (GNRI) is an easily calculable index that can be determined using three common clinical variables. The GNRI is suggested to be related to sarcopenia...
7.
Metabolic dysfunction-associated steatotic liver disease criteria may underestimate the number of lean female nonalcoholic fatty liver disease patients with significant liver fibrosis
Kobayashi N, Tada T, Nishimura T, Matono T, Yuri Y, Takashima T, et al.
Hepatol Res . 2023 Nov; 54(5):429-438. PMID: 38015179
Aim: It remains unclear whether the newly defined concept of metabolic dysfunction-associated steatotic liver disease (MASLD) appropriately includes patients with nonalcoholic fatty liver disease with significant liver fibrosis. Methods: A...
8.
Association of PNPLA3 SNP With the Development of HBV-related Hepatocellular Carcinoma
Enomoto H, Aizawa N, Ikeda N, Takashima T, Yuri Y, Okamoto M, et al.
In Vivo . 2023 Mar; 37(2):763-770. PMID: 36881106
Background/aim: Concomitant nonalcoholic fatty liver disease (NAFLD)/hepatic steatosis (HS) is suggested to increase the risk of hepatocellular carcinoma (HCC) in hepatitis virus B (HBV)-infected patients. Patatin-like phospholipase domain-containing 3 (PNPLA3)...
9.
Metastasis of Hepatocellular Carcinoma in the Pouch of Douglas Successfully Treated by Radiation Therapy: A Case Report
Enomoto H, Fujiwara M, Kono H, Kako Y, Takahagi M, Taniguchi J, et al.
Life (Basel) . 2023 Jan; 13(1). PMID: 36676174
Metastasis of hepatocellular carcinoma (HCC) in the pouch of Douglas is relatively rare. A 65-year-old man with liver cirrhosis was admitted for detailed examination of a pelvic tumor. He had...
10.
Diagnosis of hepatic steatosis based on ultrasound attenuation imaging is not influenced by liver fibrosis
Yuri M, Nishimura T, Tada T, Yoshida M, Fujiwara A, Kawata S, et al.
Hepatol Res . 2022 Aug; 52(12):1009-1019. PMID: 36018852
Aim: Recently, a new technique using attenuation imaging (ATI) was developed to diagnose hepatic steatosis. The aim of this study was to investigate whether ATI for the evaluation of hepatic...